| Year |
Citation |
Score |
| 2024 |
Morandell J, Monziani A, Lazioli M, Donzel D, Döring J, Oss Pegorar C, D'Anzi A, Pellegrini M, Mattiello A, Bortolotti D, Bergonzoni G, Tripathi T, Mattis VB, Kovalenko M, Rosati J, et al. co-evolving with the CAG-repeat tract - modulates Huntington's disease phenotypes. Molecular Therapy. Nucleic Acids. 35: 102234. PMID 38974999 DOI: 10.1016/j.omtn.2024.102234 |
0.384 |
|
| 2022 |
Hiller BM, Marmion DJ, Thompson CA, Elliott NA, Federoff H, Brundin P, Mattis VB, McMahon CW, Kordower JH. Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease. Npj Regenerative Medicine. 7: 24. PMID 35449132 DOI: 10.1038/s41536-022-00221-y |
0.353 |
|
| 2021 |
Vatine GD, Shelest O, Barriga BK, Ofan R, Rabinski T, Mattis VB, Heuer H, Svendsen CN. Oligodendrocyte progenitor cell maturation is dependent on dual function of MCT8 in the transport of thyroid hormone across brain barriers and the plasma membrane. Glia. PMID 33956384 DOI: 10.1002/glia.24014 |
0.517 |
|
| 2021 |
Le Cann K, Foerster A, Rösseler C, Erickson A, Hautvast P, Giesselmann S, Pensold D, Kurth I, Rothermel M, Mattis VB, Zimmer-Bensch G, von Hörsten S, Denecke B, Clarner T, Meents J, et al. The difficulty to model Huntington's disease in vitro using striatal medium spiny neurons differentiated from human induced pluripotent stem cells. Scientific Reports. 11: 6934. PMID 33767215 DOI: 10.1038/s41598-021-85656-x |
0.438 |
|
| 2020 |
Machiela E, Jeloka R, Caron NS, Mehta S, Schmidt ME, Baddeley HJE, Tom CM, Polturi N, Xie Y, Mattis VB, Hayden MR, Southwell AL. The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. Frontiers in Aging Neuroscience. 12: 524369. PMID 33192449 DOI: 10.3389/Fnagi.2020.524369 |
0.333 |
|
| 2019 |
Mathkar PP, Suresh D, Dunn J, Tom CM, Mattis VB. Characterization of Neurodevelopmental Abnormalities in iPSC-Derived Striatal Cultures from Patients with Huntington's Disease. Journal of Huntington's Disease. PMID 31381521 DOI: 10.3233/JHD-180333 |
0.425 |
|
| 2019 |
Garcia VJ, Rushton DJ, Tom CM, Allen ND, Kemp PJ, Svendsen CN, Mattis VB. Huntington's Disease Patient-Derived Astrocytes Display Electrophysiological Impairments and Reduced Neuronal Support. Frontiers in Neuroscience. 13: 669. PMID 31316341 DOI: 10.3389/Fnins.2019.00669 |
0.717 |
|
| 2019 |
Kedaigle AJ, Fraenkel E, Atwal RS, Wu M, Gusella JF, MacDonald ME, Kaye JA, Finkbeiner S, Mattis VB, Tom CM, Svendsen C, King AR, Chen Y, Stocksdale JT, Lim RG, et al. Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites. Human Molecular Genetics. PMID 30768179 DOI: 10.1093/Hmg/Ddy430 |
0.58 |
|
| 2018 |
Mehta SR, Tom CM, Wang Y, Bresee C, Rushton D, Mathkar PP, Tang J, Mattis VB. Human Huntington's Disease iPSC-Derived Cortical Neurons Display Altered Transcriptomics, Morphology, and Maturation. Cell Reports. 25: 1081-1096.e6. PMID 30355486 DOI: 10.1016/J.Celrep.2018.09.076 |
0.434 |
|
| 2018 |
Hung CL, Maiuri T, Bowie LE, Gotesman R, Son S, Falcone M, Giordano JV, Gillis T, Mattis V, Lau T, Kwan V, Wheeler V, Schertzer J, Singh K, Truant R. A Patient-Derived Cellular Model for Huntington's Disease Reveals Phenotypes at Clinically Relevant CAG Lengths. Molecular Biology of the Cell. mbcE18090590. PMID 30256717 DOI: 10.1091/Mbc.E18-09-0590 |
0.48 |
|
| 2018 |
Geater C, Hernandez S, Thompson L, Mattis VB. Cellular Models: HD Patient-Derived Pluripotent Stem Cells. Methods in Molecular Biology (Clifton, N.J.). 1780: 41-73. PMID 29856014 DOI: 10.1007/978-1-4939-7825-0_4 |
0.487 |
|
| 2018 |
Akhtar AA, Gowing G, Kobritz N, Savinoff SE, Garcia L, Saxon D, Cho N, Kim G, Tom CM, Park H, Lawless G, Shelley BC, Mattis VB, Breunig JJ, Svendsen CN. Inducible Expression of GDNF in Transplanted iPSC-Derived Neural Progenitor Cells. Stem Cell Reports. PMID 29706501 DOI: 10.1016/J.Stemcr.2018.03.024 |
0.699 |
|
| 2018 |
Mattis VB, Svendsen CN. Huntington modeling improves with age. Nature Neuroscience. PMID 29476127 DOI: 10.1038/s41593-018-0086-4 |
0.52 |
|
| 2017 |
Rindt H, Tom CM, Lorson CL, Mattis VB. Optimization of trans-Splicing for Huntington's Disease RNA Therapy. Frontiers in Neuroscience. 11: 544. PMID 29066943 DOI: 10.3389/Fnins.2017.00544 |
0.597 |
|
| 2015 |
Mattis VB, Svendsen CN. Modeling Huntington׳s disease with patient-derived neurons. Brain Research. PMID 26459990 DOI: 10.1016/j.brainres.2015.10.001 |
0.647 |
|
| 2015 |
Bernau K, Lewis CM, Petelinsek AM, Reagan MS, Niles DJ, Mattis VB, Meyerand ME, Suzuki M, Svendsen CN. In Vivo Tracking of Human Neural Progenitor Cells in the Rat Brain Using Magnetic Resonance Imaging is Not Enhanced by Ferritin Expression. Cell Transplantation. PMID 26160767 DOI: 10.3727/096368915X688614 |
0.496 |
|
| 2015 |
Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Human Molecular Genetics. 24: 3257-71. PMID 25740845 DOI: 10.1093/Hmg/Ddv080 |
0.6 |
|
| 2014 |
Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, et al. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease. Science Translational Medicine. 6: 268ra178. PMID 25540325 DOI: 10.1126/Scitranslmed.3010523 |
0.603 |
|
| 2014 |
Mattis VB, Wakeman DR, Tom C, Dodiya HB, Yeung SY, Tran AH, Bernau K, Ornelas L, Sahabian A, Reidling J, Sareen D, Thompson LM, Kordower JH, Svendsen CN. Neonatal immune-tolerance in mice does not prevent xenograft rejection. Experimental Neurology. 254: 90-8. PMID 24440640 DOI: 10.1016/J.Expneurol.2014.01.007 |
0.517 |
|
| 2013 |
Rushton DJ, Mattis VB, Svendsen CN, Allen ND, Kemp PJ. Stimulation of GABA-induced Ca2+ influx enhances maturation of human induced pluripotent stem cell-derived neurons. Plos One. 8: e81031. PMID 24278369 DOI: 10.1371/journal.pone.0081031 |
0.552 |
|
| 2013 |
Ebert AD, Shelley BC, Hurley AM, Onorati M, Castiglioni V, Patitucci TN, Svendsen SP, Mattis VB, McGivern JV, Schwab AJ, Sareen D, Kim HW, Cattaneo E, Svendsen CN. EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs. Stem Cell Research. 10: 417-27. PMID 23474892 DOI: 10.1016/J.Scr.2013.01.009 |
0.554 |
|
| 2012 |
Mattis VB, Tom Chang CW, Lorson CL. Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy. Neuroscience Letters. 525: 72-5. PMID 22819971 DOI: 10.1016/J.Neulet.2012.07.024 |
0.656 |
|
| 2012 |
Mattis V, Svendsen S, Ebert A, Svendsen C, King A, Casale M, Winokur S, Batugedara G, Vawter M, Donovan P, Lock L, Thompson L, Zhu Y, Fossale E, Atwal R, et al. A11 Induced pluripotent stem cells for basic and translational research on HD Journal of Neurology, Neurosurgery & Psychiatry. 83: A3.2-A4. DOI: 10.1136/Jnnp-2012-303524.11 |
0.682 |
|
| 2012 |
Mattis VB, Svendsen SP, Ebert A, Svendsen CN, King AR, Casale M, Winokur ST, Batugedara G, Vawter M, Donovan PJ, Lock LF, Thompson LM, Zhu Y, Fossale E, Atwal RS, et al. Induced pluripotent stem cells from patients with huntington’s disease show CAG repeat expansion associated phenotypes Cell Stem Cell. 11: 264-278. DOI: 10.1016/J.Stem.2012.04.027 |
0.63 |
|
| 2011 |
Mattis VB, Svendsen CN. Induced pluripotent stem cells: a new revolution for clinical neurology? The Lancet. Neurology. 10: 383-94. PMID 21435601 DOI: 10.1016/S1474-4422(11)70022-9 |
0.593 |
|
| 2010 |
Shababi M, Mattis VB, Lorson CL. Therapeutics that directly increase SMN expression to treat spinal muscular atrophy. Drug News & Perspectives. 23: 475-82. PMID 21031163 DOI: 10.1358/Dnp.2010.23.8.1507295 |
0.657 |
|
| 2009 |
Mattis VB, Fosso MY, Chang CW, Lorson CL. Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA. Bmc Neuroscience. 10: 142. PMID 19948047 DOI: 10.1186/1471-2202-10-142 |
0.664 |
|
| 2009 |
Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Human Molecular Genetics. 18: 3906-13. PMID 19625298 DOI: 10.1093/Hmg/Ddp333 |
0.689 |
|
| 2009 |
Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 457: 277-80. PMID 19098894 DOI: 10.1038/Nature07677 |
0.727 |
|
| 2009 |
Rose FF, Mattis VB, Rindt H, Lorson CL. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Human Molecular Genetics. 18: 997-1005. PMID 19074460 DOI: 10.1093/Hmg/Ddn426 |
0.6 |
|
| 2008 |
Mattis VB, Butchbach ME, Lorson CL. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy. Journal of Neuroscience Methods. 175: 36-43. PMID 18771690 DOI: 10.1016/J.Jneumeth.2008.07.024 |
0.646 |
|
| 2008 |
Mattis VB, Bowerman M, Kothary R, Lorson CL. A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neuroscience Letters. 442: 54-8. PMID 18601974 DOI: 10.1016/J.Neulet.2008.06.059 |
0.641 |
|
| 2006 |
Mattis VB, Rai R, Wang J, Chang CW, Coady T, Lorson CL. Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Human Genetics. 120: 589-601. PMID 16951947 DOI: 10.1007/S00439-006-0245-7 |
0.641 |
|
| 2005 |
Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Human Molecular Genetics. 14: 1199-210. PMID 15790598 DOI: 10.1093/Hmg/Ddi131 |
0.658 |
|
| Show low-probability matches. |